Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Around a quarter of untreated lung cancer patients in England are to get access to Merck, Sharp and Dohme’s Keytruda ... which could help prove it extends lives further. There will be a further ...

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo ... The new KEYNOTE-189 data will help it to tighten its grip ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

This commission does ... cancer. Iovance is testing lifileucel in combination with Merck cancer drug Keytruda to treat advanced melanoma. Lifileucel is also in testing to treat advanced lung ...

Markets rallied strongly this week as investors got a clear outcome in the presidential election and an expected interest rate cut by the Federal Reserve. Is this a relief rally, the continuation of a ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

It’s possible to catch a cold or get the flu at any time of year. But the chances of becoming sick increase during cold and ...

Extracellular vesicles (EVs) loaded with customizable anti-cancer antisense oligonucleotides suppressed cancer growth.

New study introduces a simple blood test to detect early lung damage in cancer patients ... is important because it could ...